

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 17 September 2009 has been entered.

Claims 2-4, 17-28, 36 and 39-51 have been canceled. Claims 1, 12, 14, 29, 34, 35, 37, and 52 have been amended and the amendment made of record. New claims 53-63 have been presented and made of record.

EXAMINER'S AMENDMENT

LC
1/26/10

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Attorney Gram on 17 December 2009.

Claim 1 is amended as follows:

In line 2 of the claim, please delete ", or an immunogenic fragment thereof" in between "SEQ ID NO:1" and ".".

Claim 12 is amended as follows:

In line 4 of the claim, please delete "the amino acid sequence" in between "to" and "."
And insert - - amino acids 13-27 of SEQ ID NO:1- - in between "to" and ".".

14
Claim ~~13~~ is amended as follows:
^